Search
for
Sort by
Research 30 of 330
- When hair dig into the brain, JAKi , may help!
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- 151 Efficacy and adverse effects of oral Janus kinase inhibitor (JAKi) use in patients with lichen planopilaris: a retrospective case series and systematic review
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- TĘTNIAK AORTY NA OSI CZASU – CZY, KIEDY I JAK LECZYĆ
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Role of janus kinase inhibitors in the treatment of alopecia areata
- The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
- A review of Janus kinase inhibitor use in scarring alopecia
- Evaluating dermatologists’ knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata
- Real-world experience quantifying access to JAK inhibitor care for alopecia areata patients: a patient-centered survey study
- Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
- Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- The role of janus kinases in the treatment of autoimmune skin diseases
- Therapeutic expansion of JAK inhibitors in Chinese dermatological practice: beyond atopic dermatitis to novel autoimmune frontiers
- Real‐World Outcomes and Safety of JAK Inhibitors in Paediatric Alopecia Areata: A Retrospective Multicentre Study
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- The Role of Janus Kinase Inhibitors in Dermatology
- Approach to Managing Recalcitrant Alopecia Areata with Combination Therapy: A Series of Five Cases in Black Pediatric Patients
- Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with <i>AIRE</i> gene mutation (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy, APECED syndrome) treated with ruxolitinib
- Irish dermatologists’ experience with JAK inhibitors in alopecia areata
- 93 Approach to Managing Recalcitrant Alopecia Areata With Combination Therapy: A Series of Five Cases in Black Pediatric Patients
- The Current State of Patient Adherence to Lab Monitoring Guidelines for Janus Kinase Inhibitors in Patients with Alopecia Areata.